Anika Therapeutics (ANIK) 49.16 $ANIK Anika to Present

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 11:07 AM

Anika Therapeutics (ANIK) 49.16 $ANIK

Anika to Present at the Singular Research 11th Annual Spring Select Conference on June 9, 2016
BusinessWire - Thu Jun 02, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"

technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research 11th Annual Spring Select Conference on Thursday, June 9, 2016 at 2:30 pm PT. The conference is being held at the Hilton hotel in San Francisco, CA.
ANIK: 49.16 (+0.24)

Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis
BusinessWire - Wed Jun 01, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"

technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in the European Union. CINGAL, which will be initially available in Hungary, Czech Republic, Poland, Germany, and Italy, received CE Mark approval in March 2016 to treat pain associated with osteoarthritis. CINGAL will be marketed and sold in Europe by a network of experienced commercial partners under the terms of their respective commercialization agreements.
ANIK: 49.16 (+0.24)

Anika Therapeutics Announces Canadian Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis of the Knee
BusinessWire - Thu May 19, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"

technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in Canada. CINGAL received Health Canada approval in October 2015 to treat pain associated with osteoarthritis of the knee.
ANIK: 49.16 (+0.24)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 50.78 (-1.50), OMED: 11.81 (-0.04), LGND: 113.74 (-1.34), ANIK: 49.16 (+0.24)

Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:40PM CDT
Alexion (ALXN) reported earnings of 87 cents per share, below the Zacks Consensus Estimate of 91 cents.
EBS: 42.30 (-1.19), ALXN: 135.61 (-2.63), AEGR: 1.37 (-0.13), ANIK: 49.16 (+0.24)

Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 76.68 (-0.95), ANIP: 52.05 (-1.64), ANIK: 49.16 (+0.24), ALQA: 1.11 (-0.03)

GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:06PM CDT
Glaxo (GSK) reported first-quarter 2016 core earnings of 57 cents per American depositary share, missing the Zacks Consensus Estimate of 60 cents.
EBS: 42.30 (-1.19), GSK: 40.93 (-1.13), ANIK: 49.16 (+0.24), NVS: 78.94 (-1.57)

Baxalta (BXLT) Beats on Q1 Earnings, Set to Merge with Shire
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:41AM CDT
Baxalta's (BXLT) first-quarter 2016 earnings of 47 cents per share beat the Zacks Consensus Estimate by a penny.
BAX: 44.49 (-0.26), SHPG: 177.10 (-6.85), BXLT: 46.02 (-0.18), ANIK: 49.16 (+0.24)

Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:27AM CDT
Bristol-Myers' (BMY) first-quarter 2016 earnings (excluding special items) of 74 cents per share easily beat the Zacks Consensus Estimate of 66 cents.
EBS: 42.30 (-1.19), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08), ANIK: 49.16 (+0.24)

Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:05AM CDT
Celgene Corp. (CELG) reported first-quarter 2016 earnings of $1.18 per share (including share-based compensation expense), beating the Zacks Consensus Estimate of $1.05.
EBS: 42.30 (-1.19), AEGR: 1.37 (-0.13), ANIK: 49.16 (+0.24), CELG: 102.91 (-3.22)

Immunomedics (IMMU) Catches Eye: Stock Moves 10.8% Higher
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 7:15AM CDT
Immunomedics Inc. (IMMU) shares rose almost 11% in the last trading session.
IMMU: 3.05 (-0.08), ANIK: 49.16 (+0.24)

Downgrade Alert for Anika Therapeutics (ANIK)
Comtex SmarTrend(R) - Thu Apr 28, 3:36AM CDT
Anika Therapeutics (NASDAQ:ANIK) was downgraded from Outperform to Market Perform at Northland today. The stock closed yesterday at $44.64 on volume of 513,000 shares, above average daily volume of 148,000. There is potential upside of 14.2% for shares of Anika Therapeutics based on a current price of $44.64 and an average consensus analyst price target of $51.00. Anika Therapeutics shares have support at the 50-day moving average (MA) of $44.62 and additional support at the 200-day MA of $38.85.
ANIK: 49.16 (+0.24)

Anika beats 1Q profit forecasts
Automated Insights - Wed Apr 27, 4:05PM CDT
BEDFORD, Mass. (AP) _ Anika Therapeutics Inc. (ANIK) on Wednesday reported first-quarter earnings of $6.9 million.
ANIK: 49.16 (+0.24)

Anika Reports First Quarter 2016 Financial Results
BusinessWire - Wed Apr 27, 3:05PM CDT
--Commenced $25 million Accelerated Share Repurchase Program
ANIK: 49.16 (+0.24)

Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:57AM CDT
Bayer (BAYRY) reported core earnings of $2.61 per share, above the Zacks Consensus Estimate of $2.48.
CYTX: 2.27 (-0.01), AEGR: 1.37 (-0.13), ANIK: 49.16 (+0.24)

New Strong Buy Stocks for April 27th
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:41AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ALGN: 78.83 (-0.86), AMCX: 60.36 (-0.63), AEGR: 1.37 (-0.13), ANIK: 49.16 (+0.24), ADTN: 18.83 (-0.16)

Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 3:31AM CDT
Oncothyreon Inc (ONTY) shares rose almost 12% in the last trading session.
ANIK: 49.16 (+0.24), ONTY: 1.21 (+0.02)

Top 5 Stocks with Increasing Cash Flows
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 2:24PM CDT
One must look at a company's ability to produce cash - the lifeblood of business.
JBT: 62.46 (-0.88), FOR: 12.35 (-0.32), NSAT: 6.36 (-0.29), EBS: 42.30 (-1.19), ANIK: 49.16 (+0.24)

Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss
Arpita Dutt - Zacks Investment Research - Thu Apr 21, 9:17AM CDT
Biogen's (BIIB) first-quarter earnings were well above expectations though Tecfidera revenues declined sequentially.
BIIB: 246.13 (-4.33), EBS: 42.30 (-1.19), GILD: 84.45 (-1.32), ANIK: 49.16 (+0.24)

Amgen's (AMGN) Phase III Study Results on Nplate Published
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 10:50AM CDT
Amgen's (AMGN) phase III study results on Nplate in children with symptomatic immune thrombocytopenia were published in The Lancet.
EBS: 42.30 (-1.19), AMGN: 154.78 (-2.00), ANIK: 49.16 (+0.24), NVS: 78.94 (-1.57)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZEISS Expands in China: Tackling Myopia's Surge

ZEISS Sets Sights on China’s Myopia Epidemic They're calling myopia a public health crisis in China, and if you've seen the statistics, that's no exaggeration. Enter ZEISS Medical Technology, angling for a piece of the pie with their newly NMPA-approved PT LUNANA phakic intraocular lens. This is more than just another medical product, folks. It's a strategic entry into...

Netcapital Faces Legal Storm: Class Action Alert

Litigation Clouds Hover Over Netcapital Every seasoned investor knows, when there's smoke, there's usually fire lurking somewhere. And boy, oh boy, is Netcapital Inc. (NASDAQ: NCPL) currently engulfed in quite a storm of controversy. This isn't your run-of-the-mill market hiccup — we're talking about a full-blown class action lawsuit sailing through the courts, with...

Global Push to End Holiday Hunger: A Crucial Initiative

Holiday Hunger: A Plight We Must Address I'll tell you what really gets under my skin—watching kids go hungry during what's supposed to be the most joyous time of the year. It's the holiday season, folks, and while many of us are fretting over gift lists, millions of children aren't even sure where their next meal is coming from. That's where Feed the Children's newest...

Portable Tombstone Urn: A Shift in Memorial Traditions

An Uncommon Approach to Remembering Loved Ones Read this on a plane, in a crowded office, or in a graveyard—doesn't matter. The heart of human stories lies buried in traditions. But here's one: portable tombstones, shake things up more than Aunt Edna’s offbeat “nonalcoholic” eggnog. This time, it's not about the latest market tickers or skyrocketing stock but...

Jumptuit's AI Patent Promises Health Alerts Innovation

Jumptuit's Patent: A Game-Changer in Health Tech Alright, strap in—Jumptuit just nabbed a patent that might flip the script on how we think about environmental health risks. The U.S. Patent and Trademark Office finally gave Donald Leka and his brainchild, Jumptuit, the green light on something they're calling 'AI Systems and Methods for Environmental Exposure and Early...

Giti Tire Hits Jaw-Dropping Speeds with Record-Breaker

Blazing a New Trail in Automotive Excellence Who would've thought rubber on road could hit a jaw-dropping 503.17 km/h (312.65 mph)? Giti Tire just broke the mold, etching its name into the history books with the Guinness World Records™ title for their GitiSport e.GTR2 Pro tires. This isn't just about speed—it's about engineering marvel and pushing boundaries in...

OpenAssets Sets Up Shop in Abu Dhabi, Joins Hub71

OpenAssets Carves a Niche in Abu Dhabi OpenAssets has just staked a claim in the Middle East by setting up its headquarters in the Abu Dhabi Global Market (ADGM). Picture this: a digital asset infrastructure provider unfurling its wings in one of the most dynamic economic landscapes—it's like watching a rookie clinch the game at the stock pit. But there's more, folks....

Maternal Role in Type 1 Diabetes: A Non-Genetic Angle

Unveiling the Maternal Puzzle in Type 1 Diabetes So here's a stumper: how come kids of moms with type 1 diabetes dodge the disease more than kids of dads with it? Simple genes don't account for it, says a study from University of Colorado Anschutz. With nearly 7,000 kids in this research, you'd think they'd find a genetic smoking gun. Nope. It's pointing to something else...

ACR Poker Kicks Off $20M Series with Key Wins

ACR Poker's High Stakes Launch with $20M Series In the world of online poker, where fortunes are won and lost faster than you can say 'all in,' ACR Poker has just dealt a monumental hand. On November 8th, they kicked off their Online Super Series (OSS) with a staggering $20 million guarantee that's got every poker aficionado buzzing. Not to mention, they crowned their...

Unveiling Federal Credit Lab: A Platform Revolution

Navigating the Maze of Federal Lending Well, folks, in the tangled web of federal economics, there's a new player aiming to bring some much-needed clarity. Lafayette Square Institute and the Center for USA Lending have rolled out the Federal Credit Lab. Think of it as a treasure trove of data and insights on federal credit, set to become a trusty compass for policymakers,...